Telavancin, a hope against Methicillin Resistant Staphylococcus aureus

Authors

  • Nazish Babar Department of Microbiology, Fazaia Medical College, Air University, Islamabad
  • Mushtaq Gill Department of Microbiology, CMH, Lahore
  • Mehreen Gilani Department of Microbiology Army Medical College, Rawalpindi
  • Javaid Usman Department of Microbiology, Quetta Institute of Medical Sciences
  • Hijab Shah Department of Pathology, Fazaia Medical College, Air University, Islamabad

Keywords:

MRSA, Telavancin, VISA and VRSA

Abstract

Objective: To determine the in vitro efficacy of Telavancin against Methicillin resistant Staphylococcus aureus.

Methods: This cross-sectional study was conducted at the Department of Microbiology, Army Medical College, Islamabad/Military Hospital, Rawalpindi, from 1st Nov 2012 to 30th June 2013. The authors aimed at assessing the in vitro efficacy of Telavancin against Methicillin resistant Staphylococcus aureus by E strip method as this study will be a help in determining guidelines for the interpretation of our local susceptibility breakpoint criteria for Telavancin against possibly emerging vancomycin intermediate Staphylococcus aureus and vancomycin resistant Staphylococcus aureus. Should vancomycin resistance become wide spread alternative therapies for methicillin resistant Staphylococcus aureus will be urgently needed.

Results: In this study 102 methicillin resistant Staphylococcus aureus were isolated, and all were found to be 100% susceptible to Telavancin.

Conclusion: Telavancin has excellent in vitro activity against methicillin resistant Staphylococcus aureus

Downloads

Published

2019-10-01

Issue

Section

Original article

How to Cite

1.
Babar N. Telavancin, a hope against Methicillin Resistant Staphylococcus aureus. Int J Pathol [Internet]. 2019 Oct. 1 [cited 2024 Jul. 14];17(2):57-61. Available from: https://jpathology.com/index.php/OJS/article/view/440

Most read articles by the same author(s)